Topical Pilocarpine Formulation for Diagnosis of Cystic Fibrosis.
clinical trial(s) formulation
iontophoresis
permeation enhancer(s)
skin
Journal
Journal of pharmaceutical sciences
ISSN: 1520-6017
Titre abrégé: J Pharm Sci
Pays: United States
ID NLM: 2985195R
Informations de publication
Date de publication:
05 2020
05 2020
Historique:
received:
09
01
2020
revised:
27
01
2020
accepted:
29
01
2020
pubmed:
10
2
2020
medline:
22
6
2021
entrez:
10
2
2020
Statut:
ppublish
Résumé
Cystic fibrosis is diagnosed in infants by estimating the levels of chloride ions present in the sweat induced by iontophoresis of pilocarpine solution. Elevated levels of chloride (≥60 mMol/L) in sweat are indicative of cystic fibrosis. However, the iontophoretic method of delivering pilocarpine is cumbersome and usually is associated with several side effects such as skin burn, skin rashes, erythema, and so forth. The objective of this study was therefore to develop a topical formulation that delivers adequate amount of pilocarpine. The drug delivery of formulation was compared with iontophoresis of aqueous solution of pilocarpine nitrate in vitro using porcine skin model. The pilocarpine levels in the skin exposed to topical pilocarpine solution under mild hyperthermia was 152.04 ± 52.23 μg/cm
Identifiants
pubmed: 32035925
pii: S0022-3549(20)30070-8
doi: 10.1016/j.xphs.2020.01.030
pii:
doi:
Substances chimiques
Chlorides
0
Pilocarpine
01MI4Q9DI3
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1747-1751Informations de copyright
Copyright © 2020 American Pharmacists Association®. Published by Elsevier Inc. All rights reserved.